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ABSTRACT 
Laser-Assisted in Situ Keratomileusis (LASIK) is a common surgery for the correction of refractive errors. The majority of 
patients who undergo this procedure often have excellent results. However, uncontrolled autoimmune disorders and dry 
eye have both been listed as contraindications to this surgery. Lichen planus (LP) is an autoimmune, inflammatory 
disorder that characteristically affects mucocutaneous membranes. The etiology is unknown, but it most commonly 
affects middle-aged adults and presents with bilateral, purple papules. Clinical presentation is used to diagnose the 
condition, and a punch biopsy is confirmatory. LP may present with multiple different symptoms depending on the type, 
with ocular manifestations being rare. Multiple viruses and autoimmune conditions have been associated with the 
disorder, and physicians should take care when gathering a full history of the patient. Exacerbation of symptoms may 
happen if mood disorders such as depression and anxiety are not well controlled. There are several additional factors 
physicians must carefully consider before recommending LASIK to patients with LP. These include lichenoid reactions, 
current medications, and past or present ocular lesions. LASIK may be carefully considered in patients with well-
controlled LP in the absence of ocular manifestations. Patients with ocular LP are not candidates for LASIK. 
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INTRODUCTION
Laser-Assisted in Situ Keratomileusis (LASIK) is a common 
surgical option for the correction of refractive errors. In 
appropriately selected patients, excellent uncorrected 
distance vision may be achieved in more than 90% of 
cases [1]. In general, patients with uncontrolled 
autoimmune disorders do not undergo the procedure 
[2]. One such disorder is Lichen planus (LP), which can 
present with ocular manifestations. This raises concerns 
about healing after LASIK due to abnormalities in the 
ocular surface such as dry eye, blepharitis, and 
conjunctival cicatricial changes [3]. These complications 
not only interfere with suction and flap creation during 
the procedure but may also result in improper 
postoperative wound healing. Although uncommon, 
ophthalmologists will likely encounter LP patients in the 
clinical setting.  
We aim to highlight considerations given to patients with 
LP seeking corneal refractive surgery. 
METHODS 
To find information on LP, a literature search was 
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Scholar, Embase, and Scopus with the keywords “Lichen 
planus,” “ocular manifestations of lichen planus,” 
“cornea lichen planus,” and “conjunctiva lichen planus.” 
Reference lists of these articles were used to find 
additional articles. There were no language restrictions. 
Publications were drawn between the dates of 1990-
2019. 
Lichen Planus and LASIK 
LP is a chronic, inflammatory autoimmune disorder 
affecting mucocutaneous membranes such as the skin, 
oral cavity, and vagina. Cutaneous LP, the most common 
type, is classically characterized by pruritic, purple, 
bilateral papules (Fig. 1) [4, 5]. The disorder is 
uncommon, presenting in roughly 1% of the population 
[5]. Middle-aged adults are most commonly affected by 
LP, with the disorder showing a slight female 
predominance [6]. 
 
Figure 1: Pruritic and Purple Papules on the Right Forearm of a 43 
Years Old Woman with a Diagnosis of Cutaneous Lichen Planus (LP) 
(Courtesy of Dr. Mirghorbani). 
 
The etiology of LP is unknown, but mechanisms have 
been hypothesized [5]. LP involves a T-cell mediated 
response that recruits dendritic cells into layers of the 
epithelium [7]. This occurs as a result of inflammation 
caused by altered self-antigens [7]. It is a clinical 
diagnosis confirmed by punch biopsy [4, 5]. 
Histopathology reveals lymphocyte infiltration and IgM 
deposition in the dermal-epidermal junction, which helps 
differentiate LP from other autoimmune disorders [4, 5, 
8].  
Hepatitis C virus (HCV), Human Papillomavirus (HPV), and 
Epstein-Barr virus (EBV) are seen more frequently in 
patients with LP [4, 9]. HCV occurs five times more often 
in patients with LP [4]. There is a significantly increased 
prevalence of HPV and EBV in LP patients [4, 9]. Human 
Papillomavirus can cause malignant transformation of LP 
lesions, but it is inconclusive whether EBV may do the 
same [9, 10]. Stress, anxiety, and mood disorders have 
shown to increase the risk of exacerbations, with stress 
specifically known to induce lesions in asymptomatic 
individuals [4]. Because of this, mood disorders should be 
well controlled before and after LASIK. A few reports 
have also noted LP to occur in conjunction with other 
autoimmune disorders including Sjogren’s Syndrome and 
Systemic Lupus Erythematosus, but no relationship has 
been discovered [4, 8, 11].  
Development of ocular symptoms is extremely rare, as in 
the last twenty years only 40 cases of ocular involvement 
have been documented [3]. Ocular manifestations of LP 
can include cicatrizing conjunctivitis, blepharitis, and 
lacrimal duct obstruction [12-14]. Conjunctivitis ranges 
from inflammation to scarring of the conjunctiva, which 
can lead to subepithelial fibrosis and dry eye (Fig. 2) [13, 
15]. Obstruction of the lacrimal ducts can lead to 
epiphora and increased risk of infection [3]. Through 
damage to the Meibomian glands, blepharitis can cause 
decreased tear production and worsening dry eye 
symptoms [13]. Many of the ocular symptoms have been 
seen together [3]. Corneal manifestations of LP 
independent from conjunctivitis are incredibly rare and 
have only been documented once [3, 15]. This case 
presented with pigmented spots on the cornea [3, 15]. 
One diagnostic challenge that physicians face is 
determining whether a patient presents with true LP or a 
lichenoid reaction. Lichenoid reactions are lesions caused 
by medications, which may persist weeks to months after 
cessation of the offending drug [4]. Common causes of 
lichenoid reactions include antimicrobials, insulin, 
sulfonylureas, anti-inflammatories, antimalarials, 
antipsychotics, chemotherapeutics, and cardiovascular 
drugs [4]. Contact lichenoid reactions may occur from 
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Figure 2: Ocular Involvement was detected in the Same Patient 
Mentioned in Figure 1. A: Obvious Fornix Shortening and Medial 
Symblepharon of the Upper Eyelid. B: Inferior Bulbar and Forniceal 
Conjunctival Staining with Rose Bengal Indicating Mucosal Disruption 
of these Areas (Photos Courtesy of Dr. Mirghorbani). 
 
First-line treatments for cutaneous and oral LP are 
acitretin (a retinoid) and topical corticosteroids 
respectively [16]. During clinical trials, 10%-25% of 
patients on acitretin developed dry eyes [17]. In addition, 
there are rare reports of corneal ulceration and keratitis 
related to the use of acitretin [18]. Because of this, we 
recommend that patients undergo evaluation for 
adequate tear production via Schirmer tear test and tear 
quality via tear film breakup time [19]. If these values are 
within normal limits, LASIK may be considered. For 
widespread cases of LP, high-dose systemic 
corticosteroids of 0.5-1.0 mg/kg/day are the treatment of 
choice [20]. Treatment regimens for these cases last for 
at least four weeks before tapering off to a lower 
maintenance dose [5, 20]. However, corticosteroid use 
for at least 30 days preoperatively at doses of 40 mg/day 
has shown to increase wound complication rates 2-5 
times [21]. We do not recommend LASIK if patients are 
taking corticosteroids  more than 40 mg/day. 
Recently, biologics, including Rituximab, have been 
shown to be effective treatments for LP [22, 23]. 
However, Rituximab has been associated with Herpes 
Simplex Virus keratitis [24]. The combination of topical 
Cyclosporine A (CsA) and a corticosteroid has shown to 
be effective in treating conjunctivitis and corneal lesions 
in LP [3, 25, 26]. However, this medication regimen only 
seems to delay progression; after cessation of treatment, 
symptoms worsen [3]. While CsA is an 
immunosuppressant, it does not appear to cause an 
increased risk for opportunistic infections [27]. There are 
reports of ocular findings related to CsA, but these 
appear to require high doses of systemic therapy [28]. 
While treatment with biologics is not an absolute 
contraindication to LASIK, we recommend close post-op 
monitoring with a low threshold to treat.  
Due to the chronic and irreversible nature of the changes 
caused by ocular LP, it is generally not recommended 
that patients with ocular symptoms undergo LASIK or any 
other corneal refractive surgeries [3]. The corneal flap 
created by LASIK can increase symptoms of dry eye, 
which combined with LP-related ocular manifestations 
can lead to severe dry eye, corneal melt, and potentially 
corneal perforation. LP can be exacerbated by a 
multitude of factors ranging from anxiety to trauma [4, 
26]. Patients with ocular LP should understand that any 
visual improvement made with LASIK may reverse during 
the next exacerbation of LP. 
Physicians should be aware of a few pre-operative and 
postoperative considerations, including current or past 
ocular symptoms, coexisting autoimmune conditions, 
medications that can cause a lichenoid reaction, and LP 
treatment regimens. A multi-disciplinary approach, 
including input from dermatology and rheumatology, is 
recommended. A complete ocular examination paying 
specific attention for small symblepharon, fornix 
shortening, adequate tear production, and probing of the 
canaliculi and the nasolacrimal duct is strongly suggested 
as these may predict the course of the disease after any 
ocular procedure (Fig. 2A). Conjunctival staining with 
rose bengal and lissamine green are important tests to 
evaluate ocular surface integrity (Fig. 2B) as they show 
mucosal disruption. Emphasis should be placed on 
frequent lubrication post-operatively, and any epithelial 
insults should be managed aggressively and immediately. 
Informed consent must be obtained with an emphasis on 
risk for severe dry eye, keratitis, corneal melt, and 
corneal perforation. However, ocular findings are 
exceedingly rare, and LASIK may be a reasonable option 
in patients with well-controlled LP in the absence of 
ocular involvement. Table 1 is a summary of pre- and 
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Table 1: Pre- and Post-LASIK Considerations For Physicians Assessing 
Lichen Planus Patients For Laser-Assisted in Situ Keratomileusis 
(LASIK). 
Special care in Lichen planus patients undergoing LASIK  
Pre-operative assessments 
Medications causing a lichenoid reaction 
Ask patient about history of Epstein-Barr virus, Human 
Papillomavirus, Hepatitis C virus infections 
Consultation with dermatologist/rheumatologist 
Psychiatric consultation if patients have comorbid anxiety/mood 
disorder 
Detailed history concerning past or present use of 
biologics/corticosteroids/retinoids such as acitretin 
Slit-lamp examination with staining looking for fornix shortening, 
small symblepharon, mucosal disruption 
Probing of canaliculi and nasolacrimal ducts 
Comprehensive review of symptoms investigating past or recent 
exacerbations of Lichen planus 
Coexisting autoimmune disorders (e.g. Systemic Lupus 
Erythematosus, Sjogren’s Syndrome) 
Post-operative considerations 
Careful monitoring and control of coexisting autoimmune disorders 
Control anxiety/any mood disorders 
Increased risk of delayed wound healing, dry eye, corneal melt, 
corneal perforation, and viral or bacterial keratitis 
Aggressive management with a low threshold to treat any 
symptoms of dry eye 
CONCLUSION 
Like most autoimmune conditions, patients with LP  must 
be carefully evaluated before considering them for 
elective refractive procedures such as LASIK. LP can 
present with a multitude of symptoms, requiring a 
multidisciplinary approach to care. When well-controlled, 
patients with this disorder may reasonably undergo 
LASIK after a comprehensive physical and history. 
Patients should be informed that ocular manifestations 
of LP can lead to permanent damage to the cornea, and 
that refractive surgeries such as LASIK are a high risk 
procedure to them. 
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